Analyst Research

Report Title Price
Provider: S&P Capital IQ Quantitative Report
$115.00
Provider: Stock Traders Daily
$20.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Keryx Biopharmaceuticals Inc Announces FDA Acceptance For Filing Of Zerenex New Drug Application


Tuesday, 8 Oct 2013 08:30am EDT 

Keryx Biopharmaceuticals, Inc announced that its New Drug Application (NDA) for Zerenex (ferric citrate coordination complex) has been accepted for filing by the U.S. Food and Drug Administration (FDA). The acceptance for filing of the NDA indicates the determination by the FDA that the application is sufficiently complete to permit a substantive review. 

Company Quote

13.23
-0.11 -0.82%
23 Jan 2015